Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Moderate Buy” by Analysts

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $124.2727.

Several research analysts have weighed in on DNTH shares. Truist Financial raised their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wedbush upped their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. HC Wainwright lifted their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th.

Dianthus Therapeutics Trading Up 1.9%

Dianthus Therapeutics stock opened at $112.11 on Wednesday. Dianthus Therapeutics has a 52 week low of $22.81 and a 52 week high of $117.88. The stock has a market cap of $6.13 billion, a P/E ratio of -27.01 and a beta of 1.22. The stock has a 50 day moving average of $101.97 and a 200-day moving average of $86.07.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, equities analysts predict that Dianthus Therapeutics will post -3.83 earnings per share for the current fiscal year.

Insider Activity

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares in the company, valued at $2,424,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Anne Mcgeorge sold 7,750 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $109.01, for a total value of $844,827.50. Following the transaction, the director owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. The trade was a 86.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 287,084 shares of company stock valued at $29,615,923 over the last three months. 3.02% of the stock is currently owned by company insiders.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently bought and sold shares of DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Dianthus Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after buying an additional 6,323 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Dianthus Therapeutics by 31.1% during the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after buying an additional 4,962 shares during the last quarter. Alliancebernstein L.P. boosted its position in shares of Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after buying an additional 149,200 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $27,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.